Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers
Epistemonikos ID: d8aa45779f7cd38868fa2ee1518d328545503cec
First added on: Mar 31, 2026